Quality of life in ovarian cancer patients treated with bevacizumab: a meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, Desantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi: 10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Rassy E, Vermorken J, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75:102045. doi: 10.1016/j.canep.2021.102045
   PubMed Web of Science ®Google Scholar
• Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253. doi: 10.1016/S0140-6736(18)32552-2
   PubMed Web of Science ®Google Scholar
• Shah S, Cheung A, Kutka M, et al. Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. 2022;19(13):8113. doi: 10.3390/ijerph19138113
   PubMed Web of Science ®Google Scholar
• Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. doi: 10.1136/bmj.m3773
   PubMed Web of Science ®Google Scholar
• Revythis A, Limbu A, Mikropoulos C, et al. Recent insights into PARP and immuno-checkpoint inhibitors in Epithelial ovarian cancer. Int J Environ Res Public Health. 2022;19(14):8577. doi: 10.3390/ijerph19148577
   PubMed Web of Science ®Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. The Lancet Oncology. 2015;16(8):928–936. doi: 10.1016/S1470-2045(15)00086-8
   PubMed Web of Science ®Google Scholar
• Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of Bevacizumab for primary treatment of ovarian cancer. JCO. 2019;37(26):2317–2328. doi: 10.1200/JCO.19.01009
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308. doi: 10.1200/JCO.2013.51.4489
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. JCO. 2012;30(17):2039–2045. doi: 10.1200/JCO.2012.42.0505
   PubMed Web of Science ®Google Scholar
• Coleman RL, Brady MF, Herzog J, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–791.
   PubMed Web of Science ®Google Scholar
• Moss HA, Havrilesky LJ. The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care. Gynecol Oncol. 2018;148(1):12–18. doi: 10.1016/j.ygyno.2017.11.011
   PubMed Web of Science ®Google Scholar
• Joly F, Hilpert F, Okanoto A, et al. Fifth ovarian cancer consensus conference of the Gynecologic cancer InterGroup: recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. Eur J Cancer. 2017;78:133–138. doi: 10.1016/j.ejca.2017.03.019
   PubMed Web of Science ®Google Scholar
• Monk BJ, Huang HQ, Burger RA, et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology group study. Gynecologic Oncology. 2013;128(3):573–578. doi: 10.1016/j.ygyno.2012.11.038
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
   PubMed Web of Science ®Google Scholar
• Hilpert F, Bois DA. Patient-reported outcomes in ovarian cancer: are they key factors for decision making? Expert Rev Anticancer Ther. 2018;18(sup1):3–7. doi: 10.1080/14737140.2018.1516146
   PubMed Web of Science ®Google Scholar
• Gnanasakthy A, Norcross L, Romano DC, et al. A review of patient-reported outcome labeling of FDA-Approved New drugs (2016-2020): counts, categories, and comprehensibility. Value Health. 2022;25(4):647–655.
   PubMed Web of Science ®Google Scholar
• Nama V, Nordin A, Bryant A. Patient-reported outcome measures for follow-up after gynaecological cancer treatment. Cochrane Database Syst Rev. 2013;2013(11):CD010299.
   PubMedGoogle Scholar
• Higgins J, Thoma J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane. 2022. Available from: www.training.cochrane.org/handbook
   Google Scholar
• Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–822. doi: 10.1001/jama.2013.879
   PubMed Web of Science ®Google Scholar
• Stark D, Nankivell M, PUJADE-LAURAINE E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the international collaboration on ovarian neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013;14(3):236–243. doi: 10.1016/S1470-2045(12)70567-3
   PubMed Web of Science ®Google Scholar
• Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13):1309–1316.
   PubMed Web of Science ®Google Scholar
• S WY, Shui L, Shen D, et al. Bevacizumab combined with chemotherapy for ovarian cancer an updated systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2017;8(6):10703–10713. doi: 10.18632/oncotarget.12926
   PubMedGoogle Scholar
• Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of cancer quality of life questionnaire core 30. Eur J. 2012;48(11):1713–1721. doi: 10.1016/j.ejca.2012.02.059
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in Oncology. JNCI Journal Of The National Cancer Institute. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. JCO. 1993;11(3):570–579. doi: 10.1200/JCO.1993.11.3.570
   PubMed Web of Science ®Google Scholar
• Puhan MA, Soesilo I, Guyatt GH, et al. Combining scores from different patient reported outcome measures in meta-analyses: when is it justified? Health Qual Life Outcomes. 2006;4:94. doi: 10.1186/1477-7525-4-94
   PubMed Web of Science ®Google Scholar
• Luckett T, King MT, Butow PN, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 2011;22(10):2179–2190. doi: 10.1093/annonc/mdq721
   PubMed Web of Science ®Google Scholar
• Friedlander M, Mercieca-Bebber RL, M T KING. Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. Ann Oncol. 2016;27(Suppl 1):i66–i71. doi: 10.1093/annonc/mdw080
   PubMedGoogle Scholar